#USA #New York #Class Action #Stock Loss #MoonLake Immunotherapeutics

Legal Notice for Shareholders of MoonLake Immunotherapeutics

In a significant development for investors of MoonLake Immunotherapeutics (NASDAQ: MLTX), a notice has been issued by The Gross Law Firm urging shareholders who faced financial losses to consider participating in a class action lawsuit. This initiative is designed to ensure that affected investors are given the opportunity to recover their losses stemming from a series of alleged misleading statements made by the company's board.

Background of the Case

The class action pertains to events that occurred between March 10, 2024, and September 29, 2025. During this period, it is alleged that the company's leadership made materially false statements and omitted vital information regarding its main drug candidate, SLK, and its relationship with BIMZELX. These claims are fundamental for shareholders who purchased MLTX shares in this time frame and may have seen their investments significantly affected.

Allegations of Misleading Information

The allegations highlight several critical issues:
1. Molecular Targets Overlap: It was claimed that both SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F, a fact that, if disclosed, would have altered investor perception of SLK's uniqueness.
2. Clinical Advantage Questioned: The distinct Nanobody structure of SLK was marketed as superior; however, the complaint argues that it does not confer any clinical benefits over the traditional monoclonal structure used in BIMZELX.
3. Questionable Efficacy: Claims about SLK's supposed increased tissue penetration failing to translate into clinical effectiveness have also been noted, challenging the basis of positive investor sentiment.
4. Unwarranted Optimism: Given these circumstances, it appears that the company lacked a reasonable foundation for its optimistic statements about SLK, misleading investors about the prospects of their stock.

Class Action Details

Shareholders interested in joining the class action should register before the deadline of December 15, 2025. This is a crucial step for anyone who acquired MLTX shares during the defined period. Once registered, shareholders will be monitored throughout the legal proceeding via a portfolio monitoring software, keeping them updated on the progress of the case.

The Gross Law Firm emphasizes that registering as a lead plaintiff is not a prerequisite for recovery, allowing for broader participation from affected investors without the burdens of additional legal complexities.

Next Steps for Investors

• - Registration: Investors can register their interest for the class action via the designated link provided by The Gross Law Firm.
• - Monitor Developments: Stay informed with updates about the case to understand when significant advances occur.

The law firm, nationally recognized for its efforts in class actions, aims to safeguard the rights of investors suffering from the adverse effects of corporate misconduct. Their commitment is to hold companies accountable and push for responsible business practices in the interest of all stakeholders affected.

If you believe you are eligible to participate in this lawsuit, it is advisable to act promptly and protect your interests.

For more information or to connect with The Gross Law Firm, investors can reach out at the contact details provided in their official notice.

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903

This notice serves as a pivotal moment for shareholders of MoonLake Immunotherapeutics wishing to seek justice and recovery for their financial interests.